Item 8.01. Other Events
On February 4, 2013, Takeda Pharmaceutical Company Limited ("Takeda") announced,
in its "Consolidated Financial Results for the Nine Month Period Ended
December 31, 2012" webcast, net product sales of OMONTYSŪ (peginesatide)
Injection for the nine month period ended December 31, 2012 of 2.8 billon yen.
This equated to $34.6 million U.S. dollars in OMONTYS net product sales for that
period as reported to Affymax, Inc. by Takeda.
OMONTYS, a synthetic, peptide-based erthropoiesis stimulating agent, was
approved in March 2012 by the United States Food and Drug Administration for the
treatment of anemia due to chronic kidney disease in adult patients on dialysis
in the U.S.
Add
AFFY to Portfolio
Set Alert
Email to a
Friend